Pharmaceutical manufacturers are aggressively expanding production capacity for GLP-1 receptor agonists. Supply constraints have prompted multi-billion-dollar capital injections into sterile filling facilities globally.
Contract Manufacturing Demand
Contract Development and Manufacturing Organizations are experiencing record backlogs as primary drug makers outsource fill-finish capacity to circumvent internal bottlenecks.
Market Dynamics
The rapid scaling of production is projected to normalize wholesale acquisition costs over the next 24 months, expanding access in international healthcare systems.